drugset / Trial / NCT00228982

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

NCT00228982

Phase 3 Completed 784 enrolled Basilea Pharmaceutica
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.

Timeline

Start
2004-10
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftobiprole medocaril Small molecule 500 mg
Comparator Vancomycin Other / unclassified 1 g